

# Gerald Illerhaus

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2399088/publications.pdf>

Version: 2024-02-01

24  
papers

2,732  
citations

759233

12  
h-index

713466

21  
g-index

24  
all docs

24  
docs citations

24  
times ranked

3606  
citing authors

#	ARTICLE	IF	CITATIONS
1	Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1697-1708.	10.7	532
2	Chemoimmunotherapy with methotrexate, cytarabine, thiopeta, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> , the, 2016, 3, e217-e227.	4.6	442
3	Targetable genetic features of primary testicular and primary central nervous system lymphomas. <i>Blood</i> , 2016, 127, 869-881.	1.4	429
4	Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer. <i>JAMA Oncology</i> , 2017, 3, 1237.	7.1	296
5	High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 3865-3870.	1.6	272
6	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , the, 2017, 4, e510-e523.	4.6	258
7	High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. <i>Haematologica</i> , 2008, 93, 147-148.	3.5	189
8	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. <i>Lancet Haematology</i> , the, 2016, 3, e388-e397.	4.6	128
9	High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix). <i>BMC Cancer</i> , 2016, 16, 282.	2.6	53
10	High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. <i>Blood Advances</i> , 2020, 4, 3378-3381.	5.2	34
11	Novel agents for primary central nervous system lymphoma: evidence and perspectives. <i>Blood</i> , 2018, 132, 681-688.	1.4	23
12	Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients. <i>BMC Cancer</i> , 2019, 19, 287.	2.6	22
13	High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Primary CNS Lymphoma: Updated Results from a Pilot and Phase II Study. <i>Blood</i> , 2008, 112, 3594-3594.	1.4	17
14	Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1300-1307.	2.8	9
15	Treatment Regimens for Immunocompetent Elderly Patients with Primary Central Nervous System Lymphoma: A Scoping Review. <i>Cancers</i> , 2021, 13, 4268.	3.7	9
16	A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells. <i>Leukemia and Lymphoma</i> , 2019, 60, 334-340.	1.3	7
17	Comment on “Primary Central Nervous System (CNS) Lymphoma B Cell Receptors Recognize CNS Proteins”. <i>Journal of Immunology</i> , 2015, 195, 4549-4550.	0.8	5
18	PCNSL: biomarker better than biopsy?. <i>Blood</i> , 2011, 117, 2987-2989.	1.4	2

#	ARTICLE	IF	CITATIONS
19	CNS relapse in DLBCL: a calculable risk?. Blood, 2021, 137, 1011-1012.	1.4	2
20	Actionable Genetic Features of Primary Testicular and Primary Central Nervous System Lymphomas. Blood, 2014, 124, 74-74.	1.4	2
21	Elimination of Established Risk-Factors in Primary Central Nervous System Lymphoma - Impact of High-Dose Chemotherapy Followed by Autologous Stem-Cell Transplantation - a Multicenter Retrospective Analysis. Blood, 2011, 118, 3089-3089.	1.4	1
22	Primary CNS lymphoma and secondary involvement of the central nervous system. Memo - Magazine of European Medical Oncology, 2009, 2, 146-149.	0.5	0
23	Mathematical Modeling in Optimizing Methotrexate-Based Chemotherapy.. Blood, 2009, 114, 4766-4766.	1.4	0
24	Therapeutic Granulocyte Transfusions in Neutropenic Patients with Invasive Pulmonary Aspergillosis,. Blood, 2011, 118, 3372-3372.	1.4	0